SOLIGENIX, INC.
SNGX · XNASCIK 812796fmd_1502VKQA2Y52Y33BGBANJADEJ8Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2010 to Sep 30, 2026, 66 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 10 | 5 | 5 | 5 | 2 | 1 | 1 | 1 | 0 | – |
| Cost of revenue | 8 | 4 | 5 | 4 | 2 | 1 | 1 | 1 | 0 | – |
| Net interest income | 0 | – | – | 0 | (0) | (1) | – | – | – | – |
| Gross profit | 2 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | – |
| Research and development | 4 | 6 | 7 | 8 | 10 | 8 | 8 | 3 | 5 | 7 |
| Total operating expenses | 8 | 9 | 10 | 12 | 19 | 13 | 15 | 8 | 9 | 12 |
| Operating income | (6) | (8) | (9) | (11) | (19) | (13) | (14) | (8) | (9) | (12) |
| Interest expense | – | – | – | – | 0 | – | – | – | – | – |
| Interest and investment income | – | – | 0 | 0 | – | – | – | – | – | – |
| Other non-operating income (expense) | 2 | 0 | 0 | 1 | 0 | (0) | (1) | (0) | 1 | 0 |
| Income before taxes | (4) | (8) | (9) | (10) | (19) | (13) | (15) | (8) | (9) | (12) |
| Income tax expense | (1) | (0) | – | (1) | (1) | (1) | (1) | (2) | (0) | (1) |
| Net income from continuing operations | (3) | (7) | – | (9) | (18) | (13) | (14) | (6) | (8) | (11) |
| Net income | (3) | (7) | (9) | (9) | (18) | (13) | (14) | (6) | (8) | (11) |
| Net income to common shareholders | (3) | (7) | – | – | (18) | (13) | (14) | (6) | (8) | (11) |